Mark Bodenrader - 01 Jun 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Title: Senior Vice President, Finance and Chief Accounting Officer
Signature: /s/ Mark Bodenrader
Issuer symbol: N/A
Transactions as of: 01 Jun 2023
Net transactions value: -$62,440
Form type: 4
Filing time: 05 Jun 2023, 20:07:33 UTC
Previous filing: 08 Feb 2023
Next filing: 21 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise		+4,733	+176%		7,417	01 Jun 2023	Direct	F1, F2
transaction	CERE	Common Stock	Sale	$62,440	-1,895	-26%	$32.95	5,522	02 Jun 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Restricted Stock Units	Options Exercise	$0	-4,733	-25%	$0.000000	14,199	01 Jun 2023	Common Stock	4,733		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.
F2	Includes 2,684 shares previously acquired under the Issuer's Employee Stock Purchase Plan.
F3	The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and intended to qualify under Rule 10b5-1.
F4	On June 1, 2022, the Reporting Person was granted 18,932 RSUs under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. 25% of the RSUs vest on each of the first, second, third and fourth anniversary of June 1, 2022, subject to the Reporting Person's continued service relationship with the Issuer through each such date.

Remarks:

Title: Senior Vice President, Finance and Chief Accounting Officer